Biotie's Financial Statement Report and Corporate Governance Statement 2013 published

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE         4 March 2014 at 9.00 a.m.

Biotie's Financial Statement Report and Corporate Governance Statement 2013 published

Biotie Therapies Corp.' s  Financial Statement Report for the financial period ended 31 December 2013 and  Corporate Governance Statement 2013 have been published.

The documents are attached in pdf format in this release. Both documents are also available on Biotie's website www.biotie.com in English and Finnish language.

Turku, 4 March 2014

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail: virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com  

About Biotie  

 Biotie is a specialized drug development company focused primarily on products for neurodegenerative and psychiatric disorders. For the past years, Biotie has successfully operated a strategy built around search, profile and partner. This has delivered Selincro (nalmefene) for alcohol dependency, which received European marketing authorization in February 2013 and is currently being rolled out across Europe by partner H. Lundbeck A/S, and tozadenant, a novel A2a antagonist which is transitioning into Phase 3 development for Parkinson's disease in collaboration with UCB Pharma S.A.. Biotie also has exclusive rights through an option to acquire Neurelis Inc., which includes NRL-1, an intranasal formulation of diazepam for epileptic seizure management. Biotie plans to seek further opportunities of this kind to generate a strong portfolio of products.  Biotie's shares are listed on Nasdaq OMX Helsinki.  

Biotie_Financial statements 2013
Biotie_Corporate Governance Statement 2013